Royalty Report: Drugs, Biotechnology, Stem cells – Collection: 3304

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Biotechnology
  • Stem cells
  • Therapeutic
  • Medical
  • Supply
  • Cancer
  • Drug Discovery
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3304

License Grant
The Undisclosed Licensee entered into an exclusive License Agreement with this unrelated Chinese-based Licensor to develop and commercialize hepatocellular carcinoma stem cells in the territory of China, Hong Kong, Macau, and Taiwan. The Agreement has an initial term of seven years.
License Property
Hepatocellular carcinoma stem cells – Cells of the Iiver.
Field of Use
The Licensee develops cell based therapeutics that prevent, treat, cure, or regenerate damaged or aged tissue, cells and organs and restoring their normal function.

IPSCIO Record ID: 28541

License Grant
University grants Licensee an Exclusive license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory. Licensee may grant sublicenses in the Licensed Field of Use only during the Exclusive term and only if Licensee is developing or selling Licensed Products, Required Sublicensing.
License Property
University has an assignment of an invention a target and associated compounds useful for regenerative medicine. It is entitled Notch-Mediated Tissue and Organ Repair through Control of Endogenous Stem and Progenitor Cell Behavior.

Licensed Patent means U.S. Patent Application, Serial Number 11/078,899.  

Stem cells have a capacity both for self-renewal and the generation of differentiated cell types. This pluripotentiality makes stem cells unique. In addition to studying the important normal function of stem cells in the regeneration of tissues, researchers have further sought to exploit the potential of in situ and/or exogenous stem cells for the treatment of a variety of disorders. While early, embryonic stem cells have generated considerable interest, the stem cells resident in adult tissues may also provide an important source of regenerative capacity.

11/078,899 (7,837,993) The regenerative potential of aged stem cells is enhanced by activation of the Notch signaling pathway and/or inhibition of TGF-ß signaling pathway. Stem cells in aged tissues are capable of proliferation and tissue regeneration, but in their native setting are not provided with the appropriate signals to do so. By administering tissue regenerating agents, organ stem/progenitor cells are provided with the appropriate signals to regenerate the corresponding differentiated tissues.

Field of Use
Licensed Field of Use means therapeutic uses and associated internal research and drug screening activities.

IPSCIO Record ID: 382728

License Grant
German Licensor granted an exclusive license in the field of certain human stem cells.
License Property
Human stem cells relates to replacing damaged tissues and to help the body regenerate after injury.

Licensor has the unique strength of combining stem cell research focused on different organs and developmental stages with leading expertise in cellular plasticity, epigenetics and disease models. This unique combination has led to breakthrough discoveries at the crossroads between disease models and repair, cellular plasticity and disease as well as reprogramming.

Field of Use
Field of use is used in the medical industry relating to stem cells.

IPSCIO Record ID: 7550

License Grant
The Licensee obtained a non-exclusive License to distribute human embryonic stem cell lines made by the Licensor through stem cell banks.
License Property
The term “stem cells” describe all of the cells that can give rise to the different cells found in tissues.  Cells from the same pluripotent stem cells can be used in any patient. This type of cell therapy is referred to as “allogeneic”. This permits the use of a single master stem cell bank in the manufacturing of the therapeutic doses to be used such that one uniform source of starting cells can be readily controlled for consistency, lack of infectious agents and cleared by regulatory agencies.

IPSCIO Record ID: 47933

License Grant
The Spanish University patent families referred to as PCX006 and PCX007 are the subject of a co ownership agreement with the Spanish Licensee. Under the terms of this agreement, the University assigned all exploitation rights, including the right to license or sub-license to third parties.
License Property
University signed an agreement for the Assignment of the Rights to Exploit Spanish invention patents no. 200402355, entitled “IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE”, and no. 200402083, entitled “Biomaterial for suture”

PCX006 is a patent family claiming a non osteochondral derived multipotent adult stem cell population characterized by a set of biological markers.
PCX007 is a patent family claiming an adipose derived stem cell composition characterized by a panel of cell surface markers, methods of preparation of such a composition and adipose tissue derived stromal stem cells in treating fistula and wounds.

(WO2006037649/11/167,061) IDENTIFICATION AND INSOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
The present invention relates to isolated multipotent adult cells which are isolated from non-osteochondral mesenchymal tissue and are characterized by the presence and absence of a set of cell surface markers. The invention also relates to a method for identifying and isolating a population of said cells, as well as to the applications thereof, for example, in the manufacture of a pharmaceutical composition for the repair and regeneration of tissues.

Field of Use
The Licensee is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells.

IPSCIO Record ID: 263

License Grant
The Hospital hereby grants the Licensee an exclusive, royalty-bearing license under its Patent Rights in the License Field and the License Territory.
License Property
Pathfinder Cells shall mean a mixed population of mammalian cells, with a mixed CD90 positive phenotype and CD34 negative phenotype, isolated using the methodology described in the patent WO/2006/120476, and which are capable of facilitating, or initiating the repair of mammalian tissue following, by way of example only, insult with an exogenous agent, or degenerative disease, or through the biological ageing processes.

Patent rights shall mean the U.S. Patent Application Number 11/438,790, filed on May 22, 2006 or the equivalent of such application as well as issued patent applications including U.S. Patent Application Number 11/410, 412, 10/984, 645, and 11/132, 687.

Field of Use
Pathfinder Cells are a newly identified mammalian cell type  that have the ability to stimulate tissue regeneration in a number of different organs. PCs are not stem cells and are distinguishable from cell types being developed by other companies for use in regenerative medicine through cell surface and other markers.

IPSCIO Record ID: 26667

License Grant
We acquired the Exclusive worldwide rights to US Patent # 6129911, for Liver Stem Cells from Licensor, a non-profit  hospital.  The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.
License Property
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.  (The Company has an exclusive, long-term license agreement for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs)  US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;  US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;  US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;  US Patent #4,795,459, Implantable Prosthetic Device (Endothelial), expires January 3, 2006;  US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;  US Patent #6,858,146, Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and  US Patent #6,872,389, Liver Stem Cell, expires on July 8, 2019.)

IPSCIO Record ID: 276397

License Grant
Licensee obtains rights in mainland China, Hong Kong, Macau and Taiwan to develop and commercialize enoblituzumab.
License Property
Enoblituzumab is an investigational, Fc-optimized mAb that targets B7-H3. MacroGenics recently met with FDA to discuss its plans regarding a Phase 2/3 registration-directed study of enoblituzumab in combination with MGA012 in patients with squamous cell carcinoma of the head and neck (SCCHN).

A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.